# Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

> **NCT06771934** · — · ACTIVE_NOT_RECRUITING · sponsor: **Qianfoshan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Allergic Asthma

## Interventions

- **BIOLOGICAL:** Allergen-specific immunotherapy(AIT)
- **BIOLOGICAL:** omalizumab

## Key facts

- **NCT ID:** NCT06771934
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771934, "Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06771934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*